Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Oksana Shlobin"'
Autor:
Christopher Thomas, Abhimanyu Chandel, Christopher S. King, Shambhu Aryal, A. Whitney Brown, Vikramjit Khangoora, Alan Nyquist, Anju Singhal, Onix Cantres Fonseca, Oksana Shlobin, Steven D. Nathan
Publikováno v:
Pulmonary Circulation, Vol 13, Iss 2, Pp n/a-n/a (2023)
Abstract COVID‐19 related lung disease (CRLD) has emerged as an indication for lung transplantation (LT) in highly select patients. The prevalence and prognostic implication of coexisting pulmonary hypertension (PH) in patients with CRLD listed for
Externí odkaz:
https://doaj.org/article/6ee5e7f16f584fdfb562f8b88c9b069e
Autor:
Dan Grinnan, Le Kang, Christine DeWilde, David Badesch, Raymond Benza, Todd Bull, Murali Chakinala, Teresa DeMarco, Jeremy Feldman, Hubert J. Ford, James Klinger, John McConnell, Erika B. Rosenzweig, Jeffrey Sager, Oksana Shlobin, Roham Zamanian, the PHAR Investigators
Publikováno v:
Pulmonary Circulation, Vol 12, Iss 3, Pp n/a-n/a (2022)
Abstract Outcomes of patients with pulmonary arterial hypertension (PAH) may be associated with social determinants of health (SDOH) and other baseline patient characteristics. At present, there is no prognostic model to predict important patient out
Externí odkaz:
https://doaj.org/article/61036673f119443280e53edc38a6388d
Autor:
Sandeep Sahay, Vijay Balasubramanian, Humna Memon, Abby Poms, Eduardo Bossone, Kristine Highland, Dana Kay, Deborah J Levine, Christopher J Mullin, Lana Melendres‐Groves, Stephen C Mathai, Francisco J Soto, Oksana Shlobin, Jean M Elwing
Publikováno v:
Pulmonary Circulation, Vol 12, Iss 2, Pp n/a-n/a (2022)
Abstract Pulmonary arterial hypertension (PAH) is a chronically progressive fatal disease. A goal‐oriented approach to achieve low risk status has been associated with improved survival. A variety of risk stratification tools are available, but use
Externí odkaz:
https://doaj.org/article/10dc882d91c940ca9de32b077a366fb3
Autor:
Laurent Savale, Marloes Huitema, Oksana Shlobin, Vasilis Kouranos, Steven D. Nathan, Hiliaro Nunes, Rohit Gupta, Jan C. Grutters, Daniel A. Culver, Marco C. Post, Daniel Ouellette, Elyse E. Lower, Tamara Al-Hakim, Athol U Wells, Marc Humbert, Robert P. Baughman
Publikováno v:
European Respiratory Review, Vol 31, Iss 163 (2022)
Sarcoidosis-associated pulmonary hypertension (SAPH) is an important complication of advanced sarcoidosis. Over the past few years, there have been several studies dealing with screening, diagnosis and treatment of SAPH. This includes the results of
Externí odkaz:
https://doaj.org/article/dda98efd4d394a34ac6c034933daf568
Autor:
Shoaib Fakhri, Kelly Hannon, Kelly Moulden, Ryan Peterson, Peter Hountras, Todd Bull, James Maloney, Teresa De Marco, Dunbar Ivy, Thenappan Thenappan, Jeffrey S. Sager, John J. Ryan, Sula Mazimba, Russel Hirsch, Murali Chakinala, Oksana Shlobin, Matthew Lammi, Dianne Zwicke, Jeffrey Robinson, Raymond L. Benza, James Klinger, Daniel Grinnan, Stephen Mathai, David Badesch
Publikováno v:
Pulmonary Circulation, Vol 10 (2020)
Background WHO Group 1 pulmonary arterial hypertension is a progressive and potentially fatal disease. Individuals living at higher altitude are exposed to lower barometric pressure and hypobaric hypoxemia. This may result in pulmonary vasoconstricti
Externí odkaz:
https://doaj.org/article/4a56ac6498194904b41f9cd0ff053f23
Autor:
Gustaf Wigerblad, Seth A. Warner, Marcos J. Ramos-Benitez, Lela Kardava, Xin Tian, Rui Miao, Robert Reger, Mala Chakraborty, Susan Wong, Yogendra Kanthi, Anthony F. Suffredini, Stefania Dell’Orso, Stephen Brooks, Christopher King, Oksana Shlobin, Steven D. Nathan, Jonathan Cohen, Susan Moir, Richard W. Childs, Mariana J. Kaplan, Daniel S. Chertow, Jeffrey R. Strich
Publikováno v:
Science advances, vol 9, iss 1
Spleen tyrosine kinase (SYK) is a previously unidentified therapeutic target that inhibits neutrophil and macrophage activation in coronavirus disease 2019 (COVID-19). Fostamatinib, a SYK inhibitor, was studied in a phase 2 placebo-controlled randomi
Autor:
Christopher S. King, Emily White, Shambhu Aryal, Oksana Shlobin, Anju Singhal, A. Whitney Brown, Christopher Thomas, Vikramjit Khangoora, Alan Nyquist, Kevin Flaherty, Steven D. Nathan, Joshua J. Mooney
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9f3bd58b8be7136aef389bc10b246815
https://doi.org/10.2139/ssrn.4335526
https://doi.org/10.2139/ssrn.4335526
Autor:
Christine Y. Zhou, Sandeep Sahay, Oksana Shlobin, Francisco J. Soto, Stephen C. Mathai, Lana Melendres-Groves, Christopher J. Mullin, Deborah J. Levine, Dana Kay, Kristin Highland, Eduardo Bossone, Abby Poms, Humna Memon, Vijay Balasubramanian, Mary Jo S. Farmer, Franck Rahaghi, Jean M. Elwing
Publikováno v:
Respiratory medicine. 206
The coronavirus of 2019 (COVID-19) disrupted delivery of healthcare. Patients with pulmonary hypertension (PH), especially pulmonary arterial hypertension (PAH), require significant resources for both diagnosis and management and are at high risk for
Autor:
Jeff Min, Rui Feng, David Badesch, Erika Berman-Rosenzweig, Charles Burger, Murali Chakinala, Teresa De Marco, Jeremy Feldman, Anna Hemnes, Evelyn M. Horn, Matthew R. Lammi, Stephen Mathai, John W. McConnell, Kenneth Presberg, Jeffrey Robinson, Jeffrey Sager, Oksana Shlobin, Marc Simon, Thenappan Thenappan, Corey Ventetuolo, Nadine Al-Naamani, Roblee Allen, Sonja Bartolome, Raymond Benza, Todd Bull, Linda Cadaret, Michael Eggert, Jean Elwing, Jeffrey Fineman, Raymond Foley, H. James Ford, Robert Frantz, Russel Hirsch, James Grinnan, D. Dunbar Ivy, Steven Kawut, Jamie Kennedy, James Klinger, Peter Leary, Sula Mazimba, Gautam Ramani, Amresh Raina, James Runo, John Swisher, John Ryan, Nidhy Varghese, R. James White, Timothy Williamson, Delphine Yung, Roham Zamanian, Dianne Zwicke
Publikováno v:
Ann Am Thorac Soc
Rationale: Obesity is associated with pulmonary arterial hypertension (PAH), but its impact on outcomes such as health-related quality of life (HRQoL), hospitalizations, and survival is not well understood. Objectives: To assess the effect of obesity
Autor:
Sandeep Sahay, Vijay Balasubramanian, Humna Memon, Abby Poms, Eduardo Bossone, Kristine Highland, Dana Kay, Deborah J Levine, Christopher J Mullin, Lana Melendres‐Groves, Stephen C Mathai, Francisco J Soto, Oksana Shlobin, Jean M Elwing
Publikováno v:
Pulmonary circulation. 12(2)
Pulmonary arterial hypertension (PAH) is a chronically progressive fatal disease. A goal-oriented approach to achieve low risk status has been associated with improved survival. A variety of risk stratification tools are available, but use is low. We